Intravenous (IV) infusions of lg concentrates are an effective but expensive treatment for patients with autoimmune thrombocytopenic purpura (AITP). The optimal treatment protocol and the long-term results are uncertain, and the precise mechanism by which the platelet count increases is poorly understood. Twenty adult patients with chronic AITP were enrolled in a prospective study to compare the respective efficacy of two high-dose IVlgG induction regimens (1 g Y 2 g/kg body weight) and the long-term effect of six 1 g/kg body weight IVlgG reinfusions. An initial response was observed in all 18 evaluable patients: the platelet count increased to a mean value of 251 X 10g/L (range 72 to 836 X 109/L) and the mean pretreatment platelet count was multiplied by 14.6. No difference in efficiency was observed between the two IVlgG dosages. The degree of the platelet count increment correlated in both groups with the increase in the clearance of antibody-coated red blood cells, measured by an isotopic method, but not with the serum IgG elevation.
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INCE THE first report by Imbach et al,' several studies
S have confirmed that high-dose intravenous immunoglobulin G (IVIgG) infusions are effective in the treatment of patients with autoimmune thrombocytopenic purpura (AITP).' After a total infusion of 2 g of IVIgG/kg body weight, the platelet count transiently increases in 70% to 100% of patients. However, the precise platelet response mechanism has not yet been entirely established' and the exact place of such treatment in the management of these patients is controversial, in particular because of its higher cost. There is general agreement that IVIgG should be administered in emergency situations and that it is a safe preparation for ~urgery.~ In contrast, the ability of the treatment to cure chronic AITP is controversial, even if repeated IVIgG infusions have been proposed as maintenance treatand have occasionally given persistent remiss i o n~.~*~-~~ We report the results of treatment with repeated IVIgG infusions in 20 adult patients with chronic AITP. This randomized open trial was conducted to determine: (1) the respective efficiency of two IVIgG infusion regimens, ie, 1 g 0 2 g/kg body weight; (2) the long-term outcome of patients treated with repeated IVIgG infusions and the ability of the treatment to avoid splenectomy; and (3) clinical and biologic characteristics with predictive value for treatment efficacy.
PATIENTS AND METHODS

Patients
Twenty consecutive adult patients with chronic AITP were included in a randomized open prospective study. The patients were informed of the nature of the trial and its attendent risks in the presence of an independent witness, and all gave their informed consent. AITP was diagnosed according to standard criteria, ie, isolated thrombocytopenia, normal or increased megacaryocyte count in an otherwise normal bone marrow (BM) aspirate, and absence of other causes of thrombocytopenia. The eligibility criteria were as follows: no diseases known to be associated with AITP (ie, human immunodeficiency virus (HIV) infection, systemic lupus erythemaTreatment was considered to have failed in l l patients, 90 days after the last IVlgG reinfusion (DSO), because the platelet counts were comparable with pretreatment values. In contrast, a complete response was observed at D90 in five patients (mean platelet count: 184 X 109/L; range: 1 50 to 250 X 1 09/L) and a partial response at D90 was obtained in the remaining t w o patients (platelet counts: 70 and 104 X 1 09/L). Five of the 7 responders at D90 kept a platelet count above 50 X 109/L during the entire follow-up period (mean 33 months; range: 5 to 66) with no further treatment; unfortunately, no clinical or biologic criteria were found to be predictive of the long-term response. This study shows that an IVlgG infusion regimen of 1 g/kg body weight could safely replace the classical 2 g/kg body weight dosage, at least in patients who do not have life-threatening thrombocytopenia. Moreover, repeated IVlgG reinfusion could be an altemative for AITP patients in whom splenectomy is contraindicated. 0 1993 by The American Society of Hematology.
tosus and other connective tissue disorders, lymphoproliferative disorders, thyroid or liver diseases); no treatment for at least two weeks before the study; a stable, low platelet count (less than 50 X 109/L); and no life-threatening hemorrhagic syndrome. Because one goal was to test the ability of the treatment to avoid splenectomy, we included nonsplenectomized patients only 4 months after the diagnosis of AITP. However, the analysis of patient histories clearly showed that they had chronic AITP. Thus, the mean time between the date of diagnosis and the last observed abnormal platelet count was 30 months, and all the patients had thrombocytopenia for more than 6 months (range 9 to 87 months), which is the time commonly used to affirm that AITP is chronic."
IVIgG Preparation and Treatment Schedules
Unselected lots of commercially available IVIg (Biotransfusion, Roissy, France) were used. They contained more than 98% of unmodified human IgG and were obtained by Cohn ethanol fractionation with treatment at pH 4 in the presence of trace amounts of pepsin.'' Initial treatment. The patients were randomized to receive initially a total IVIgG dose of 1 g/kg body weight (group A) or 2 g/kg body weight (group B) as two divided doses on two consecutive days in both cases. The daily IVIgG dose was administered in 4 to 8 hours according to tolerance. Platelet counts were measured on days 1 (pretreatment), 2, 3, 4, 5, 6 , 11, 15, and weekly thereafter. The initial response was considered complete when the platelet count increased above 150 X 109/L and partial if it increased above 50 X 109/L and at least twice the initial count; treatment wasconsidered to have failed in the other cases. The first IVlgG booster ( I g/kg body weight in both groups) was administered when the platelet count fell below SO X 109/L; five other reinfusions (total of six boosters) were administered at the same dosage, every 2 to 3 weeks, unless a stable normal platelet count (> 150 X 109/L) was obtained or the response was exhausted.
Long-term results were evaluated 90 days (D90) after the last IVIgG booster, as follows: failure, when the platelet response was exhausted or only a transient response to each IVIgG infusion was observed; complete response, if the D90 platelet count was above 150 X 109/L; partial response, ifthe D90 platelet count was between 50 and I50 X 109/L and more than twice the initial platelet count. In addition, platelet counts were evaluated for 5 to 75 months (mean, 40 months) after the last IVIgG infusion on the occasion of return visits to the hospital.
Clinical and Biologic Correlations
Several parameters were studied in an attempt to identify correlations with the response to IVIgG infusions, as follows: age, sex, duration of disease before IVIgG treatment, response to previous steroid treatment, presence of detectable IgG platelet antibodies, ability to block the reticuloendothelial system, and IgG serum levels before and two days after the initial IVIgG infusions. Platelet antibodies were determined by means of the platelet direct (PIFT) and indirect (PIIFT) immunofluorescence tests according to the techniques described by Borne et al,l3.I4 before and 2 days after the initial IVIgG treatment, using an anti-lgG antiglobulin (Dakopatts, Copenhagen, Denmark). The ability to block the reticuloendothelial system was determined in the 15 evaluable rhesus+ patients immediately before and 24 hours after completion of IVIgG therapy and in nine healthy rhesus+ control subjects, by analyzing clearance of antibody-coated red blood cells ( (Centre National de Transfusion Sanguine, Pans, France) at 37°C for 60 minutes. After being washed twice, the RBCs were resuspended in 2 mL of saline and reinjected. Clearance was studied by counting 2 ml of each venous blood sample collected 10,20,30,45, 60, and 90 minutes after the injection in a gamma counter. The half life of sensitized RBCs (T1/2) was determined using a monoexponentia1 function. The RBC T 1/2 in the nine control subjects was 22.9 veloped in 12; they included headache (n = 8), chills (n = 6),
Group A: patients initially treated with a total dose of 1 g of IVIgG/kg fever (n = 2), myalgia (n = 2), abdominal pain and vomiting body weight. Group B: patients initially treated with a total dose of 2 g of (n = l), and a urticarial rash (n = 1). t and median: 6 days) after the first IVIgG infusion. The mean time required to reach a platelet count above 150 X 109/L in the 13 patients with complete responses after initial IVIgG infusions was 4 days (range 2 to 6; median value: 4 days). The mean percentage increase in the serum IgG concentration was significantly higher in group B (227%) than in group A ( 16 1 %) (P < .05) but, surprisingly, there was no difference in the platelet count increment between the two groups (Table 3 ). In addition, the platelet count increment correlated well with the increase in the antibody-coated RBC survival in both groups ( r = .704 in groups A and B [P < .01]; .609 in group A [P < .01]; .718 in group B [P < 0.0 I]). In contrast, none of the following factors correlated with the platelet count increment: sex, age, duration of the disease before IVIgG infusions, response to corticosteroid treatment, presence before or evolution after treatment of IgG platelet antibodies, and percentage increase in serum IgG concentration after IVIgG infusion.
IVIgG Reinfusion
Thirteen of the 18 evaluable patients received the six IVIgG boosters as planned. The other five patients received only one (n = 3) or two boosters (n = 2) because of an exhaustion of the response to IVIgG infusions in three (pts 1 1, 16, and 18), and a prolonged complete response in two (pts 2, 10).
The long-term responses were considered as failures in 1 1 patients (Table 4) . Patients 11, 16, and 18, all in group B, became refractory to IVIgG reinfusions (see above) and only a transient response was observed in the other eight (pts 1, 3, 4, 5, 6, 7, 14, 17), six of whom were in group A. Figure 1 shows the mean pre-and post-IVIgG platelet counts in these eight patients; the mean D90 platelet count was 17 X 109/L (median value: 15 X 109/L), a value comparable with the mean pretreatment count (22 X 109/L) (median value: 20 X 109/L). Six of these 1 1 patients (pts 1, 3,4, 7, 1 1, and 14) subsequently underwent splenectomy; a persistent complete response was obtained in four (pts 1, 3, 4, and 7) (mean follow-up: 40 months; range 24 to 60 months), and a transient response in one (pt 11); the last patient (pt 14) was lost to follow-up after an initially successful splenectomy. Two other patients (pts 16 and 18) achieved a complete response on danazol treatment. No further treatment was administered to the remaining three patients (pts 5, 6, and 17), in whom the platelet count remained between 15 and 30 X 109/L without bleeding complications (mean follow-up after the last IVIgG infusion: 2 1 months; range 10 to 30 months).
A complete response at D90 was observed in five patients (mean platelet count at D90: 184 X 109/L; range 150 to 250), and a partial response in two others (70 X 109/L and 104 X 109/L) ( Table 4) . Two of the patients (pts 2 It is well established that IVIgG is an effective treatment ment for the following 48 months. The complete remission for AITP but its precise place in the management of these persisted in the other patient (pt 2), 36 months after the last patients is controversial, particularly on account of its high IVIgG administration. Six IVIgG boosters were required in cost. Furthermore, more than 10 years after the first demonthe remaining five responders (three complete responses stration of its efficacy, the optimal dosage of IVIgG, toand two partial responses); the platelet counts improved gether with the best timing of the infusions, and their longgradually during treatment with IVIgG boosters (Fig 2) .
term efficacy remain uncertain. Lastly, the precise Three patients (pts 8, 9, and 15) were still in partial remismechanism of the platelet increment is unknown. Our resion at the last hospital visit, 5 , 27 and 32 months after the sults provide answers to some of these questions. last IVIgG infusion. A relapse occurred 22 months after the As previously reported by others,20.2' we found that a twolast IVIgG booster in another patient (pt 12) (described by day administration regimen rapidly increased the platelet Bierling et a]'). Multiple IVIgG reinfusions led to a further count and was well tolerated, even if minor side-effects were complete remission lasting 1 I months. The patient finally frequent. Importantly, a total infusion of 1 g IVIgG/kg body underwent successful splenectomy. A relapse occurred 14 weight was as efficient as the 2 g/kg regimen initially promonths after the last IVIgG booster in the remaining patient posed by Imbach et al.' However, there are several difficul-(pt 13), who also underwent splenectomy but with only a ties in extrapolating these results. In particular, although partial response.
Bussel et al6.'O also failed to find a significant difference beNone ofthe patients' characteristics listed in Table 5, nor tween the platelet count increment and the amount of inthe presence before or the evolution after IVIgG treatment fused IVIgG, the existence of a correlation has been sugof platelet antibodies correlated with the long-term regested in sporadic reports'7.'* and a series of patients.23 sponse, although the first IVIgG infusion tended to procure Furthermore, the lower dosage has been reported to be inefa more important platelet count increment and more durafective and a higher dosage effective in selected patients, ble effect in the long-term responders.
both same preparation as that used in this study (personal results). However, it is difficult to compare our results with others because the amount infused and the manufacturer of IVIgG concentrates, as well as the characteristics (acute or chronic) of AITP are different. Indeed, chronic AITP had been diagnosed a relatively short time previously in our patients, who did not have life-threatening hemorrhagic conditions and IVIgG has been reported to be more effective when treatment is started at an early stage of the Thus, further studies are required before the reduced IVIgG dosage can be proposed for all AITP patients, particularly those with life-threatening conditions or long-standing AITP.
Our results also confirm the ability of IVIgG treatment to procure prolonged remission after repeated booster infusions (7 of 18 patients). These favorable long-term results were probably not caused by spontaneous remissions, because our patients presented well-defined chronic AITP," as evidenced by the presence of immune platelet destruction over at least a 9-month period in all the evaluable patients, and because spontaneous remissions are very rare in chronic AITP.4 This assumption is also supported by the gradual increase in the platelet count during IVIgG reinfusion in 5 of the 7 long-term responders. Unfortunately, no factors predictive of a favorable prolonged response were identified, although the response after the first IVIgG infusion was stronger and slightly longer in the long-term responders. In view of these results, as it has been yet reported in a group of drug-resistant splenectomized patient^,^ repeated IVIgG infusions may be a safe alternative when splenectomy is contra-indicated.
The precise mechanism involved in the platelet count increment after IVIgG infusions has not yet been established. There is evidence that Fc receptor blockade, leading to a prolongation of the clearance time of circulating immune particles, may at least partly explain the immediate platelet response." Indeed, we found a correlation between the degree of Fc receptor blockade (estimated by evaluating of the clearance of antibody-coated RBCs) and the intensity of the platelet response. The quantity of IVIgG necessary to obtain this blockade is unclear, because the IVIgG dosage proposed empirically by Imbach et all is usually administered. Our results, showing that comparable Fc receptor blockade was obtained with the 1 g/kg and 2 g/kg body weight IVIgG regimens, and that the intensity of blockade did not correlate with the increase in the serum IgG concentration, could explain the similar platelet response obtained with the two dosages. Other mechanisms, particularly an idiotypic interaction,26.2' could account for the prolonged responses in some patients, because Fc receptor blockade probably does not persist when injected IVIgG is no longer present in the circulation. Unfortunately, platelet antibody studies provided no predictive markers of the long-term outcome, or further arguments to support this hypothesis.
In conclusion, our findings suggest that when IVIgG treatment is required for chronic AITP patients, a 1 g/kg body weight regimen administered in 1 or 2 days can safely replace the usual 2 g/kg regimen. However, further studies are necessary to confirm that this reduced regimen is always effective and to determine its suitability for patients with life-threatening conditions. Our results also confirm that repeated IVIgG infusions can sometimes cure chronic AITP. Because the response is unpredictable and usually partial, and as the cost of IVIgG is high, repeated IVIgG infusions should, in our opinion, only be proposed for patients in whom splenectomy is contra-indicated.
